12/18/2025
It’s a historic day for drug policy. Today, December 18, 2025, President Trump signed an executive order directing the formal rescheduling of ma*****na from Schedule I to Schedule III under the Controlled Substances Act.
This move effectively ends over 50 years of ma*****na being classified alongside drugs like he**in, which are deemed to have "no accepted medical use."
Key Changes from Today's Order
Medical Recognition: For the first time, the federal government is formally acknowledging that ma*****na has legitimate medical benefits.
Tax Relief (280E): This is massive for the industry. Moving to Schedule III means cannabis businesses will no longer be subject to IRS Section 280E, finally allowing them to deduct normal business expenses (like rent and payroll) from their federal taxes.
Research Expansion: The order directs federal agencies to fast-track and simplify the process for scientists to study the plant, which was previously buried in Schedule I red tape.
Medicare & CBD: The order also includes a pilot program to explore reimbursing Medicare patients for certain CBD products.
What Stays the Same?
It’s important to note that this is not federal legalization.
Federal Prohibition: Recreational use remains technically illegal at the federal level.
Criminal Penalties: The move doesn't automatically erase existing criminal records or stop federal enforcement for non-compliant activities.
State Markets: Your local state laws still apply; the "legal" status in your specific state hasn't changed overnight, but the federal "conflict" is now significantly lessened.
This marks a major pivot in federal policy, shifting the focus from strictly criminal enforcement to a more medical and regulated framework.
